A. Hebert, R. Schrieber, D. Glaab, and L. Eichenfield, “Phase IV Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis”, J of Skin, vol. 4, no. 6, p. s77, Oct. 2020.